Welcome to ArenaGI.com
A scientific exchange resource from Arena Medical Affairs

Arena’s Upcoming Congress Activities

View

Arena’s Activities at
UEG Week Virtual 2021

View

Arena’s Activities at
ACG 2021

Arena at 2021 United European
Gastroenterology Week Virtual

October 3-5, 2021

Connecting the dots:
Integrating mechanism of action into advanced treatment decisions in UC

P0390

Pharmacokinetics, Safety, and Tolerability of Etrasimod (APD334) in Subjects With Mild, Moderate, or Severe Hepatic Impairment: A Single-dose, Open-label, Parallel-group Study

P0428

Real-world Treatment Patterns and Healthcare Costs Among US Commercially Insured Adults Initiating Biologics for Ulcerative Colitis

P0406

Etrasimod Improves Quality of Life in Adults With Moderate-to-Severe Ulcerative Colitis: Results From the Phase 2 OASIS Trial and Open-label Extension

OP115 Oral Presentation by Dr Lin Chang, UCLA, on Monday, October 4, 2021, at 12:00 PM CEST

Efficacy and Safety of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of Cannabinoid Receptor 2, for the Treatment of Abdominal Pain in Patients With Irritable Bowel Syndrome: Results From a Phase 2b Randomized Study

Arena at 2021 American College of Gastroenterology
Annual Scientific Meeting

October 25-27, 2021

P0524

Pharmacokinetics (PK), Safety, and Tolerability of Etrasimod (APD334) in Participants With Mild, Moderate, or Severe Hepatic Impairment: A Single-dose, Open-label, Parallel-group Study

P0518

Etrasimod Improves Quality of Life in Adults With Moderate-to-Severe Ulcerative Colitis: Results From the Phase 2 OASIS Trial and Open-label Extension

P2628

Real-world Treatment (Tx) Patterns and Healthcare Costs Among US Commercially Insured Adults Initiating Biologics for Ulcerative Colitis (UC)

Clinical Trials

EXPLORE GI PROGRAMS

Publications

ACCESS OUR LIBRARY

Investigational Drugs

LEARN MORE ABOUT ETRASIMOD AND OLORINAB

The Science of Inflammatory Bowel Disease (IBD)

video-thumb

The Science of Inflammatory Bowel Disease (IBD)

We are evaluating an oral, selective S1P receptor modulator for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD).

Proposed Etrasimod MOA: S1P Receptor Modulation in IBD

Proposed Etrasimod MOA: S1P Receptor Modulation in IBD

arena-of-care-logo

Working to help meet
the needs of patients

Our work is focused on a singular purpose: to support what matters most to patients and the communities that serve them. This is our Arena of Care™.

Learn More, Including
How to Apply

For Medical Information, contact us at medinfo@arenapharm.com